New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 8, 2013
06:16 EDTGERN, INCY, SNYIncyte still well positioned in myelofibrosis, says Jefferies
Jefferies believes Incyte (INCY) remains well positioned in myelofibrosis following data abstracts on two competitors. The firm says Geron's (GERN) data for imetelstat looks promising but comes with caveats, while Incyte's Jakafi is a strong competitor to Sanofi's (SNY) fedratinib. Jefferies keeps a Buy rating on shares of Incyte.
News For INCY;GERN;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
09:16 EDTGERNOn The Fly: Pre-market Movers
Subscribe for More Information
07:20 EDTGERNGeron announces early HSR clearance for collaboration with Janssen
Subscribe for More Information
December 12, 2014
08:01 EDTINCYPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 9, 2014
11:19 EDTSNYSanofi reportedly ready to make acquisitions in animal medicine, Bloomberg says
Subscribe for More Information
07:11 EDTINCYEli Lilly and Incyte announce Phase 3 RA-BEACON study met primary endpoint
Subscribe for More Information
December 8, 2014
13:07 EDTINCYNovartis announces data from Jakavi trial
Novartis (NVS) announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi, supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively. In an analysis of 1,144 patients treated with Jakavi to date in this ongoing expanded access study, 69% of patients achieved >50% reduction in spleen size from baseline and patients also experienced a clinically meaningful improvement in myelofibrosis symptom score, important treatment goals for patients with myelofibrosis. Findings from the study were presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, California. Novartis research and development efforts, in collaboration with Incyte Corporation (INCY), include early-phase and post-marketing studies in myelofibrosis and other myeloproliferative neoplasms. More than 50 abstracts on ruxolitinib are being presented at ASH, including three oral presentations exploring combinations of ruxolitinib with various investigational compounds, evaluating the possibility of simultaneously targeting multiple cancer pathways that may be involved in the pathogenesis of myelofibrosis. The JUMP study is a Phase IIIb, expanded-access trial for countries with no access to Jakavi outside of a clinical trial. The open-label, multicenter study analyzed 1,144 enrolled myelofibrosis patients who received daily starting doses of either 5 mg, 15 mg or 20 mg of Jakavi twice daily based on platelet counts at baseline. The primary endpoint is assessment of safety and tolerability of Jakavi. Overall, the safety and efficacy profile of Jakavi was consistent with previous studies.
08:11 EDTGERNGeron to host analyst and investor meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use